EDITORIAL SECTION
-
STRATEGY
Strategic Positioning for M&A
The biotechnology sector is characterised by a constant influx of small highly specialised companies
-
RESEARCH DEVELOPMENT
Cytiva Laboratory capsule filters
Our singleuse selfcontained filtration solutions help reduce contamination risk and lower manual handling
-
CLINICAL TRIALS
Virtual Clinical Trials
Virtual digital and decentralized are all descriptions of the novel ways that using technology changes
-
Bio Pharma
Biosimilars and Biobetters
Biosimilars are biologic medical products that are essentially identical to an original product manufactured
-
MANUFACTURING
Transformative Convergence of AI in Pharmaceutical Manufacturing
The pharmaceutical manufacturing industry is on the cusp of a revolutionary transformation driven by
-
Information Technology
Transformative Impact of Artificial Intelligence on Clinical Trials
Artificial Intelligence AI has rapidly evolved from a futuristic concept to a transformative tool across various industries
-
EXPERT Talk
From Clinical Trials to Pharmacovigilance: A Multi-Agent Future
The industry has automated within silos not across them Your clinical data management systems dont communicate with safety databases Trial monitoring...
Advisory Board
.webp "Juris Hmelnickis")
.webp "Eiman Shafa")
KNOWLEDGE BANK
-
Articles
Forgotten Biology: The Missing Link Behind Trial Outcomes
Clinical trials are often described as the science of uncertainty and that uncertainty is expected It is how evidence is built However not all uncertainty is scientific In many cases it arises when the biological context of an intervention is not carried through into the study population
-
Techno Trends
FORE Biotherapeutics Receives FDA Breakthrough Therapy Designation for Plixorafenib in Brain Cancer
FORE Biotherapeutics has received Breakthrough Therapy Designation from the US Food and Drug Administration FDA for its investigational drug plixorafenib developed for the treatment of adult patients with BRAF VEmutated highgrade glioma a severe form of brain cancer
-
Projects
Cambrex Announces $150 Million Expansion across U.S. and European Facilities
Cambrex has revealed significant progress on its expansion initiatives across the United States and Europe These projects are designed to boost capacity for manufacturing complex drugs
-
Research Insights
Interpretable multivariate survival models: Improving predictions for conversion from mild cognitive impairment to Alzheimer’s disease via data fusion and machine learning
Accurately predicting which individuals with mild cognitive impairment MCI will progress to Alzheimers disease AD can improve patient care This study examines the role of quantitative MRI qMRI cognitive evaluations
-
White Papers
Accelerating In-Vitro Antibody Discovery with Artificial Intelligence
Antibodies have transformed modern medicine reshaping treatment paradigms across autoimmune disorders oncology and infectious diseases As one of the most versatile and successful therapeutic modalities
TOP ARTICLES
-
1
Innovative Therapies: How Cell and Gene Technologies are Changing Lives
Kate Williamson
Medical science stands transformed through pioneering advancements in cell and gene therapy which treat chronic diseases and genetic conditions at their foundations. Through genome-editing technologie...
-
2
Biotech Boom: How Startups are Driving U.S. Pharma Growth
Kate Williamson
An array of biotech start-ups in America are transforming the pharmacovigilance industry through novel technologies such as CRISPR, Artificial Intelligence, and Precision Medicine. Supported by fundin...
-
3
How to Use Natural Language Processing (NLP) in Pharmacovigilance?
Kate Williamson
Natural Language Processing (NLP) enhances pharmacovigilance by automating data extraction and analysis from diverse sources. This guide outlines key steps: defining objectives, data collection, annot...
-
4
How to Leverage Clinical Staff for Patient Recruitment in Healthcare?
Kate Williamson
Optimizing patient recruitment in healthcare requires a strategic approach to engage clinical staff effectively. Training, communication, a patient-centric mindset, identification tools, trust-buildin...
-
5
The Future of Drug Pricing Reforms: What Americans Need to Know
Kate Williamson
High costs of drugs have ignited legislative measures meant to bring down cost of these commodities. This is particularly the case in the U. S. Some of the key measures which have been included are Me...
press releasesRead more...
Neurizon Receives Ethics Approval for Phase 1 NUZ-001 Oral Liquid Formulation Study
Neurizon Therapeutics Limited is pleased to announce that the Bellberry Human Research Ethics Committee HREC has approved the Companys Phase formulation study supporting development of the NUZ
Creatv Bio Opens CLIA-Certified Laboratory to Support Oncology Drug Development
Creatv Bio a Division of Creatv MicroTech Inc Creatv a liquid biopsybased cancer diagnostic testing company recently opened its full service CLIAcertified laboratory in Monmouth Junction NJ
Collegium Completes Acquisition of AZSTARYS® from Corium Therapeutics
Collegium Pharmaceutical Inc today announced that it has completed the acquisition of AZSTARYS serdexmethylphenidate and dexmethylphenidate a central nervous system CNS stimulant prescription medicine used for the treatment of Attention Deficit Hyperactivity Disorder ADHD in people years of age and...
Infex Therapeutics secures £4.3 million funding to advance anti-infective pipeline targeting drug-resistant infections
Infex Therapeutics a leading antiinfectives specialist announces it has secured million in funding led by prominent British venture capitalist Jon Moulton with participation from the GMC Life Sciences Fund managed by Catapult Ventures and existing high net worth investors
Events Read more...
10 - 14
May 2026Respiratory Drug Delivery 2026
The Westin Kierland Phoenix, Arizona, USA
20 - 21
May 2026Pharmacovigilance Europe 2026
London, UK
20 - 22
May 2026PHARMA EURASIA 2026
Pharma & Med Tech Park, Tashkent, Uzbekistan
20 - 21
May 2026Pharma Partnering EU Summit 2026
Basel Marriott Hotel, Switzerland
21 - 22
May 2026Liver Diseases & Hepatology 2026
Paris, France
27 - 28
May 2026Future Labs Live 2026
Congress Center, Basel, Switzerland
27 - 28
May 2026UK Biotech Day 2026
Radisson Hotel & Conference Centre London Heathrow, UK
27 - 28
May 2026Digi-Tech Pharma & AI Conference
London, United Kingdom
LATEST NEWSRead more...
Nuvation Bio Partners with Thermo Fisher for U.S. Manufacturing of IBTROZI®
Nuvation Bio has completed the transfer of manufacturing processes for IBTROZI taletrectinib to Thermo Fisher Scientificin the United States The medicine is used to treat patients with advanced or metastatic ROSpositive nonsmall cell lung cancer NSCLC
Agios Submits sNDA to FDA for U.S. Accelerated Approval of Mitapivat in Sickle Cell Disease
Agios Pharmaceuticals Inc a commercialstage biopharmaceutical company focused on delivering innovative medicines for patients with rare diseases today announced the submission of its supplemental New Drug Application sNDA to the US Food and Drug Administration FDA for the US accelerated
Boehringer Ingelheim licenses preclinical antibody program from Immunitas Therapeutics to advance treatments for chronic inflammatory diseases
Boehringer Ingelheim and Immunitas Therapeutics today announced a global licensing agreement for a preclinical antibody program being developed for chronic inflammatory and autoimmune diseases The program is designed to selectively target cells that play a central role in driving chronic inflammatio...
Gyre Therapeutics Announces NMPA Acceptance of New Drug Application for F351 (hydronidone) for CHB-Induced Liver Fibrosis Treatment
Gyre Therapeutics Inc an innovative commercialstage biopharmaceutical company with operations in the United States and China today announced that the Center for Drug Evaluation CDE of Chinas National Medical Products Administration NMPA has accepted its New Drug Application NDA for F hydronidone
China grants breakthrough status to NHWD-870 for NUT carcinoma treatment
Chinas National Medical Products Administration NMPA has granted Breakthrough Therapy Designation to NHWD HCI an oral BET inhibitor developed by Zhejiang Wenda Pharmaceutical Technology Co Ltd
Halozyme and GSK Partner on Subcutaneous Oncology Treatments
Halozyme Therapeutics has entered into a global collaboration and licence agreement with GSK to develop subcutaneous formulations for several oncology therapies
